This information is intended for use by health professionals

1. Name of the medicinal product

Hydroxychloroquine sulfate 200mg film-coated Tablets

2. Qualitative and quantitative composition

Hydroxychloroquine sulfate 200mg

Excipients with known effect

Each tablet contains 47.5 mg of lactose.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Film Coated Tablet

4. Clinical particulars
4.1 Therapeutic indications


Treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight.

Paediatric Population

Treatment of juvenile idiopathic arthritis (in combination with other therapies), discoid and systemic lupus erythematosus.

4.2 Posology and method of administration

Adults (including the elderly)

The minimum effective dose should be employed. This dose should not exceed 6.5mg/kg/day (calculated from ideal body weight and not actual body weight) and will be either 200mg, 300mg or 400mg per day.

In patients able to receive 400mg daily:

Initially 400mg daily in divided doses. The dose can be reduced to 200mg when no further improvement is evident. The maintenance dose should be increased to 300mg or 400mg daily if the response lessens.

Paediatric Population

The minimum effective dose should be employed and should not exceed 6.5mg/kg/day based on ideal body weight. The 200mg tablet is therefore not suitable for use in children with an ideal body weight of less than 31kg.

Each dose should be taken with a meal or glass of milk.

Hydroxychloroquine is cumulative in action and will require several weeks to exert its beneficial effects, whereas minor side effects may occur relatively early. For rheumatic disease treatment should be discontinued if there is no improvement by 6 months. In light-sensitive diseases, treatment should only be given during periods of maximum exposure to light.

The tablets are for oral administration.

4.3 Contraindications

• hypersensitivity to hydroxychloroquine or to any of the excipients

• known hypersensitivity to 4-aminoquinoline compounds

• pre-existing maculopathy of the eye

4.4 Special warnings and precautions for use

Visual Effects

The occurrence of retinopathy is very uncommon if the recommended daily dose is not exceeded. The administration of doses in excess of the recommended maximum is likely to increase the risk of retinopathy, and accelerate its onset.

All patients should have an ophthalmological examination before initiating treatment with Hydroxychloroquine sulfate. Thereafter, ophthalmological examinations must be repeated at least every 12 months.

The examination should include testing visual acuity, careful ophthalmoscopy, fundoscopy, central visual field testing with a red target, and colour vision.

This examination should be more frequent and adapted to the patient in the following situations:

o daily dosage exceeds 6.5mg/kg lean body weight. Absolute body weight used as a guide to dosage could result in an overdosage in the obese

o renal insufficiency

o visual acuity below 6/8

o age above 65 years

o cumulative dose more than 200g.

Hydroxychloroquine sulfate should be discontinued immediately in any patient who develops a pigmentary abnormality, visual field defect, or any other abnormality not explainable by difficulty in accommodation or presence of corneal opacities. Patients should continue to be observed for possible progression of the changes.

Patients should be advised to stop taking the drug immediately and seek the advice of their prescribing doctor if any disturbances of vision are noted, including abnormal colour vision.

Cardiac Effects

Cases of cardiomyopathy resulting in cardiac failure, in some cases with fatal outcome, have been reported in patients treated with hydroxychloroquine sulfate (see section 4.8 and 4.9). Clinical monitoring for signs and symptoms of cardiomyopathy is advised and hydroxychloroquine sulfate should be discontinued if cardiomyopathy develops. Chronic toxicity should be considered when conduction disorders (bundle branch block / atrio-ventricular heart block) as well as biventricular hypertrophy are diagnosed (see section 4.8).

Caution is required in the following circumstances

Hydroxychloroquine sulfate should be used with caution in patients taking medicines which may cause adverse ocular or skin reactions. Caution should also be applied when it is used in the following:

o patients with hepatic or renal disease, and in those taking drugs known to affect those organs. Estimation of plasma hydroxychloroquine levels should be undertaken in patients with severely compromised renal or hepatic function and dosage adjusted accordingly.

o patients with severe gastrointestinal, neurological or blood disorders.

o caution is also advised in patients with a sensitivity to quinine, those with glucose-6-phosphate dehydrogenase deficiency, those with porphyria cutanea tarda which can be exacerbated by hydroxychloroquine and in patients with psoriasis since it appears to increase the risk of skin reactions.

o patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Blood Disorders

Although the risk of bone marrow depression is low, periodic blood counts are advisable as anaemia, aplastic anaemia, agranulocytosis, a decrease in white blood cells, and thrombocytopenia have been reported. Hydroxychloroquine sulfate should be discontinued if abnormalities develop.

Toxic effects in children

Small children are particularly sensitive to the toxic effects of 4-aminoquinolines; therefore patients should be warned to keep Hydroxychloroquine sulfate out of the reach of children.


Hydroxychloroquine has been shown to cause severe hypoglycaemia including loss of consciousness that could be life threatening in patients treated with and without antidiabetic medications. Patients treated with hydroxychloroquine should be warned about the risk of hypoglycaemia and the associated clinical signs and symptoms. Patients presenting with clinical symptoms suggestive of hypoglycaemia during treatment with hydroxychloroquine should have their blood glucose level checked and treatment reviewed as necessary.

Muscoskeletal effects

All patients on long-term therapy should undergo periodic examination of skeletal muscle function and tendon reflexes. If weakness occurs, the drug should be withdrawn.

Dermatological reactions

Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the use of Hydroxychloroquine.

Patients should be advised of the signs and symptoms and if symptoms or signs of SJS or TEN are present, Hydroxychloroquine treatment should be discontinued.

If the patient has developed SJS or TEN with the use of Hydroxychloroquine, Hydroxychloroquine must not be restarted in this patient at any time

Extrapyramidal disorders

Extrapyramidal disorders may occur with Hydroxychloroquine sulfate (see section 4.8).

4.5 Interaction with other medicinal products and other forms of interaction


Hydroxychloroquine sulfate has been reported to increase plasma digoxin levels: serum digoxin levels should be closely monitored in patients receiving combined therapy.


Hydroxychloroquine sulfate may also be subject to several of the known interactions of chloroquine even though specific reports have not appeared. These include: potentiation of its direct blocking action at the neuromuscular junction by aminoglycoside antibiotics; inhibition of its metabolism by cimetidine which may increase plasma concentration of the antimalarial; antagonism of effect of neostigmine and pyridostigmine; reduction of the antibody response to primary immunisation with intradermal human diploid-cell rabies vaccine.


As with chloroquine, antacids may reduce absorption of hydroxychloroquine so it is advised that a 4 hour interval be observed between Hydroxychloroquine sulfate and antacid dosaging.


As hydroxychloroquine may enhance the effects of a hypoglycaemic treatment, a decrease in doses of insulin or antidiabetic drugs may be required.


Halofantrine prolongs the QT interval and should not be administered with other drugs that have the potential to induce cardiac arrhythmias, including hydroxychloroquine. Also, there may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine is used concomitantly with other arrhythmogenic drugs, such as amiodarone and moxifloxacin.


An increased plasma ciclosporin level was reported when ciclosporin and hydroxychloroquine were co-administered.


Hydroxychloroquine can lower the convulsive threshold. Co-administration of hydroxychloroquine with other antimalarials known to lower the convulsion threshold (e.g mefloquine) may increase the risk of convulsions.


Also, the activity of antiepileptic drugs might be impaired if co-administered with hydroxychloroquine.


In a single-dose interaction study, chloroquine has been reported to reduce the bioavailability of praziquantel. It is not known if there is a similar effect when hydroxychloroquine and praziquantel are coadministered. Per extrapolation, due to the similarities in structure and pharmacokinetic parameters between hydroxychloroquine and chloroquine, a similar effect may be expected for hydroxychloroquine.


There is a theoretical risk of inhibition of intra-cellular α-galactosidase activity when hydroxychloroquine is co-administered with agalsidase.

4.6 Fertility, pregnancy and lactation


There is no information available on the effect of Hydroxychloroquine sulfate on human fertility. In animal studies, chloroquine, a substance related to hydroxychloroquine, showed adverse effects on male fertility (see section 5.3).


Although able to cross the placenta, the use of hydroxychloroquine in pregnancy is now considered to convey a low risk of harm to the foetus with no significant increase in congenital malformations. In SLE there is evidence that hydroxychloroquine reduces disease activity during pregnancy reinforcing the importance of continuing this therapy. Indeed, pregnancy itself can induce lupus flares, which can be prevented by hydroxychloroquine. Preliminary studies have suggested that hydroxychloroquine can reduce the risk of neonatal lupus and congenital heart block in lupus patients who are anti-Ro positive. A recently published study of pregnant patients with antiphospholipid syndrome found that exposure to hydroxychloroquine was linked to a significantly higher live birth rate.

Taken together in autoimmune diseases such as lupus and anti-phospholipid syndrome the balance of benefit outweighs any potential harm to the foetus and therefore hydroxychloroquine should be continued. In other diseases the prescribing physician should assess the risk/benefit ratio for hydroxychloroquine and act accordingly.


Data on safety during breastfeeding are limited but no harmful effects have been observed. Hydroxychloroquine is excreted in small amounts in breast milk, with estimates of exposure to infants ranging from <1% to about 3% of the adult dose. All infants exposed to hydroxychloroquine during pregnancy will also have been exposed during breastfeeding because the half-life of hydroxychloroquine is more than 40 days. Hydroxychloroquine seems to carry a low risk of harm to the infant. A careful benefit-risk assessment should be made whether to take hydroxychloroquine therapy whilst breastfeeding, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

4.7 Effects on ability to drive and use machines

Impaired visual accommodation soon after the start of treatment has been reported and patients should be warned regarding driving or operating machinery. If the condition is not self-limiting, it will resolve on reducing the dose or stopping treatment.

4.8 Undesirable effects

The following CIOMS frequency rating is used, when applicable:

Very common (≥1/10); Common(≥1/100 to <1/10) ; Uncommon(≥1/1,000 to <1/100) ; Rare(≥1/10,000 to <1/1,000); Very rare (<1/10,000) ; Not known (cannot be estimated from the available data).

Tabulated list of adverse reactions

System Organ class


Adverse reaction

Immune system disorders

Not known

Urticaria, angioedema, bronchospasm

Eye disorders


Blurring of vision due to a disturbance of accommodation which is dose dependent and reversible


Retinopathy with changes in pigmentation and visual field defects can occur, but appears to be uncommon if the recommended daily dose is not exceeded. In its early form it appears reversible on discontinuation of hydroxychloroquine sulfate. If allowed to develop, there may be a risk of progression even after treatment withdrawal.

Patients with retinal changes may be asymptomatic initially, or may have scotomatous vision with paracentral, pericentral ring types, temporal scotomas and abnormal colour vision.

Corneal changes including oedema and opacities have been reported. They are either symptomless or may cause disturbances such as haloes, blurring of vision or photophobia. They may be transient and are reversible on stopping treatment.

Not known

Cases of maculopathies and macular degeneration have been reported (the onset ranging from 3 months to several years of exposure to hydroxychloroquine) and may be irreversible

Skin and subcutaneous tissue disorders


Skin rash, Pruritus


Pigmentary disorders in skin and mucous membranes, bleaching of hair, alopecia

These usually resolve readily on stopping treatment.

Not known

Bullous eruptions including erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome) photosensitivity, exfoliative dermatitis, acute generalised exanthematous pustulosis (AGEP).

Acute generalised exanthematous pustulosis (AGEP) has to be distinguished from psoriasis, although hydroxychloroquine may precipitate attacks of psoriasis. It may be associated with fever and hyperleukocytosis. Outcome is usually favourable after drug withdrawal.

Gastrointestinal disorders

Very common

Abdominal pain, nausea


diarrhoea, vomiting

These symptoms usually resolve immediately on reducing the dose or on stopping treatment.

Nervous system disorders





Not known

Convulsions have been reported with this class of drugs. Extrapyramidal disorders such as dystonia, dyskinesia, tremor (see section 4.4).

Cardiac disorders

Not known

Cardiomyopathy which may result in cardiac failure and in some cases a fatal outcome (see SPC section 4.4 and 4.9)

Chronic toxicity should be considered when conduction disorders (bundle branch block/atrioventricular heart block) as well as biventricular hypertrophy are found. Drug withdrawal may lead to recovery.

Musculoskeletal and connective tissue disorders


Sensory motor disorders

Not known

Skeletal muscle myopathy or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups.

Myopathy may be reversible after drug discontinuation, but recovery may take many months.

Depression of tendon reflexes and abnormal nerve conduction studies.

Blood and lymphatic system disorders

Not known

Bone-marrow depression, anaemia, aplastic anaemia, agranulocytosis, leucopenia and thrombocytopenia

Hepatobiliary disorders


Abnormal liver function tests

Not known

Fulminant hepatic failure

Metablism and nutrition disorders

Not known

Hypoglycaemia (see section 4.4),

Hydroxychloroquine may precipitate or exacerbate porphyria.



Ear and labyrinth disorders


Vertigo, tinnitus

Not known

Hearing loss

Psychiatric disorders


Affect lability



Not known


Reporting of side effects

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Overdosage with the 4-aminoquinolines is dangerous particularly in infants, as little as 1-2g having proved fatal.

The symptoms of overdosage may include headache, visual disturbances, cardiovascular collapse, convulsions, hypokalaemia; rhythm and conduction disorders, including QT prolongation, Torsade de Pointes, ventricular tachycardia and ventricular fibrillation followed by sudden and early respiratory and cardiac arrest. Since these effects may appear soon after taking a massive dose, treatment should be prompt and symptomatic.

The stomach should be immediately evacuated, either by emesis or by gastric lavage. Activated charcoal in a dose at least five times of the overdose may inhibit further absorption if introduced into the stomach by tube following lavage and within 30 minutes of ingestion of the overdose.

Consideration should be given to administration of parenteral diazepam in cases of overdosage; it has been shown to be beneficial in reversing chloroquine cardiotoxicity.

Respiratory support and shock management should be instituted as necessary.

5. Pharmacological properties
5.1 Pharmacodynamic properties

ATC Code: P01BA02

Pharmacotherapeutic group: Anti rheumatic

Antimalarial agents like chloroquine and hydroxychloroquine have several pharmacological actions which may be involved in their therapeutic effect in the treatment of rheumatic disease, but the role of each is not known. These include interaction with sulphydryl groups, interference with enzyme activity (including phospholipase, NADH - cytochrome C reductase, cholinesterase, proteases and hydrolases), DNA binding, stabilisation of lysosomal membranes, inhibition of prostaglandin formation, inhibition of polymorphonuclear cell chemotaxis and phagocytosis, possible interference with interleukin 1 production from monocytes and inhibition of neutrophil superoxide release.

5.2 Pharmacokinetic properties

Hydroxychloroquine has actions, pharmacokinetics and metabolism similar to those of chloroquine. Following oral administration, hydroxychloroquine is rapidly and almost completely absorbed. In one study, mean peak plasma hydroxychloroquine concentrations following a single dose of 400mg in healthy subjects ranged from 53-208ng/ml with a mean of 105ng/ml. The mean time to peak plasma concentration was 1.83 hours. The mean plasma elimination half-life varied, depending on the post-administration period, as follows: 5.9 hours at Cmax-10 hours), 26.1 hours (at 10-48 hours) and 299 hours (at 48-504 hours). The parent compound and metabolites are widely distributed in the body and elimination is mainly via the urine, where 3% of the administered dose was recovered over 24 hours in one study.

5.3 Preclinical safety data

Animal studies concerning a cancerogenic potential of hydroxychloquine are not available. A mutagenic potential could not be excluded.

Hydroxychloroquine passes the placenta and can induce damage to organs of the fetus. In studies with mice and monkeys, chloroquine, a substance related to hydroxychloroquine, resulted in transplacental transfer and accumulation in the adrenal cortex and the retina. High maternal doses of chloroquine were fetotoxic in rats and caused anophthalmia and microophthalmia. In studies in rats, chloroquine reduced the testosterone secretion, the weight of the testis and epididymis and caused production of abnormal sperm.

6. Pharmaceutical particulars
6.1 List of excipients

Lactose Monohydrate

Maize Starch


Croscarmellose Sodium

Magnesium Stearate


Titanium Dioxide

Macrogol 6000

Iron Oxide Yellow E172

Polysorbate 80

6.2 Incompatibilities

No incompatibilities are known.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

250µm clear PVC/20µm aluminium foil blister pack containing 10 tablets.

The blister packs are packed in an outer cardboard carton containing 28, 30 or 60 tablets. Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling


7. Marketing authorisation holder

Blackrock Pharmaceuticals Ltd.

Abbey Place

24-28 Easton Street

High Wycombe

HP11 1NT

United Kingdom

8. Marketing authorisation number(s)

PL 33271/0001

9. Date of first authorisation/renewal of the authorisation

15 September 2011 /16 March 2018

10. Date of revision of the text

11 November 2020